# BioLineRx Ltd.: Form 20-F/A for the period ended Dec 31, 2023

- Company: [BioLineRx Ltd.](/companies/blrx.md) (CIK 1498403)
- Form: 20-F/A
- Filed: 2024-03-26
- Accepted by EDGAR: Mar 26, 2024, 20:57 ET
- Period: 2023-12-31
- Accession: 0001178913-24-001095
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001095/zk2431202.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001095/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $4.8m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | $3.7m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2023-01-01 to 2023-12-31 | $1.1m | ifrs-full:GrossProfit |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | −$49.7m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$60.6m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | −$0.06 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | −$0.06 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$22.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $116.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2023-12-31 | $4.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2023-12-31 | $47.2m | ifrs-full:CurrentAssets |
| Total assets | at 2023-12-31 | $63.9m | ifrs-full:Assets |
| Current liabilities | at 2023-12-31 | $30.9m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2023-12-31 | $50.7m | ifrs-full:Liabilities |
| Shareholders' equity | at 2023-12-31 | $13.2m | ifrs-full:Equity |
| Shares outstanding | at 2023-12-31 | 1,086,589,165 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1498403/000117891324001095/zk2431202.htm

Filed Mar 26, 2024.
Source: SEC EDGAR, the filing index for accession 0001178913-24-001095. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.